Phase 2 N=15 Metformin to Augment Low Milk Supply (MALMS) Study
Low Milk Supply · Pre-diabetes · Insulin Resistance
Primary: Peak Change in Milk Output — 8; -58 milliliters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=202 A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression
Depression
Primary: Double-Blind (DB) Induction Phase: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 — -15.2; -14.5; -15.1; -15.3 Units…
Phase 2 N=19 A Trial of PF-06252616 in Ambulatory Participants With LGMD2I
LGMD2I
Primary: Incidence of Dose Limiting or Intolerability Treatment Related Adverse Events — 45; 21; 40; 0 events
Phase 2 N=80 Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma
Lymphoma
Primary: Disease Response (Complete, Complete Unconfirmed, and Partial Responses) After 4 Courses — 47; 8; 14 Participants
Phase 2 N=63 Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress
Alcohol Use Disorder · Stress Disorders, Post-Traumatic · Anxiety Disorders
Primary: Change in Craving to Use Alcohol Rating (Visual Analog Scale) — 0.076; -0.928 score on a scale
Phase 2 N=252 A Safety and Immune Response Study of 2 Experimental HIV Vaccines
HIV Infection
Primary: Part A: Number of Participants Reporting Local Reactogenicity Signs and Symptoms During the Primary Vaccine Regimen — 42; 26; 126; 16 Participants
Phase 2 N=18 The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
Primary: Number of Subjects With Dose Limiting Toxicities — 0 Participants
Phase 2 N=57 A Study for Patients With Non-Hodgkin's Lymphomas
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Phase 2 N=215 Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan
Open Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure (IOP) — 20.5; 20.3; 20.8; 21.1 mmHg — p=<0.0001
Phase 2 N=124 Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndrome · MDS
Primary: Mean Decitabine Area Under the Concentration Versus Time Curve (AUC0-t) on Day 5 by Cohort in Phase 1 — 53.6; 68.9; 94.8; 221 ng*h/mL
Phase 2 N=31 Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
Hemophagocytic Lymphohistiocytosis
Primary: Overall Survival — 25 Participants
Phase 2 N=22 Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E
Fatty Liver
Primary: Biochemical: Number of Patients With Normal Transaminases at End of Treatment. — 6; 6; 6 Participants
Phase 2 N=25 A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma
Cutaneous T-Cell Lymphoma
Primary: Percentage of Participants With Confirmed Complete Response (CR) or Partial Response (PR) Among Mycosis Fungoides (MF) and Sezary Syndrome (SS) Participants (Response…
Phase 2 N=30 A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL
Leukemia
Primary: Number of Patients Treated With Alemtuzumab and Rituximab Combination With a Response (CR or PR) Assessed by NCI-WG 1996 Criteria With Lymph-adenopathy and Organomegaly…
Phase 2 N=12 Phase I/II Study of SRP-4053 in DMD Patients
Duchenne Muscular Dystrophy
Primary: Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Discontinuation — 4; 5; 5; 3 Participants